Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:
The clinical evidence base for Dotinurad comprises 1 peer-reviewed publications across 1 journals, 1 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including . Most recent publication: A Single- and Multiple-Dose Study to Characterize the Pharmacokinetics and Safety of Dotinurad in Healthy Chinese Adults., Clin Drug Investig, 2025.
Curated set of pivotal-trial result papers and recent publications in high-tier journals.
Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.
| Trial | Indication | Primary endpoint | Arm | Value |
|---|---|---|---|---|
| NCT05007392 | Gout | Percentage of Participants With Serum Uric Acid (SUA) Level <=6.0 mg/dL at Week 24 (LOCF) At Week 24 | Dotinurad | 73.6 percentage of participants |
| Febuxostat | 38.1 percentage of participants |
2025–2025: 1 publications.
In the pivotal trial for gout, NCT05007392, the primary outcome measured the percentage of participants who achieved a serum uric acid (SUA) level of 6.0 mg/dL or less at Week 24.
In the NCT05007392 study, the dotinurad arm reported that 73.6% of participants reached an SUA level of 6.0 mg/dL or less at Week 24. The febuxostat arm in the same study reported that 38.1% of participants achieved an SUA level of 6.0 mg/dL or less at Week 24.
All values presented are sourced from primary registry reporting. Individual papers should be consulted for clinical decisions.
ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.efetch.fcgi